4//SEC Filing
Fox Jennifer A. 4
Accession 0001209191-21-010330
CIK 0001811063other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 5:46 PM ET
Size
8.8 KB
Accession
0001209191-21-010330
Insider Transaction Report
Form 4
Fox Jennifer A.
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-02-10+398,935→ 398,935 totalExercise: $4.60Exp: 2030-10-11→ Class A Common Stock (398,935 underlying) - Award
Stock Option (Right to Buy)
2021-02-10+558,506→ 558,506 totalExercise: $4.60Exp: 2030-10-11→ Class A Common Stock (558,506 underlying)
Footnotes (5)
- [F1]Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer").
- [F2]Options vest as to 25% on October 12, 2021 and in equal monthly installments thereafter over the following three years.
- [F3]Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock.
- [F4]Options vest as to 20% on October 12, 2023, 20% on October 12, 2024 and 60% on October 12, 2025, subject to achievement of performance criteria.
- [F5]Received in exchange for an option to purchase 558,506 shares of Legacy Nuvation Class A Common Stock.
Documents
Issuer
Nuvation Bio Inc.
CIK 0001811063
Entity typeother
Related Parties
1- filerCIK 0001841557
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 5:46 PM ET
- Size
- 8.8 KB